亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

NHR2 inhibitors

总结

Treatment of AML by inhibitors of NHR2 and/or RUNX1/ETO-tetramerization provides a therapy option with a unique mode of action.

技术优势

Compounds for treatment of AML
Unique mode of action
Medical use/compound protection achievable
In vivo data from mouse model available
Access to inventor know-how

技术应用

Treatment of acute myeloid leukemia

详细技术说明

The formation and onset of the prevalent form of acute myeloid leukemia (AML, FAB subtype M2) requires RUNX1/ETO, the product of the t(8;21) chromosomal translocation. Tetramerization through the nervy homology region 2 (NHR2) of ETO is essential for the RUNX1/ETO-mediated transformation. The inventors demonstrated that inhibition of NHR2 tetramerization by first-in-class small molecules is a viable entry point for the treatment of AML.

合作类型

Licensing

申请日期

25/04/2014 00:00:00

申请号码

WO2014EP58449 20140425

分类

- international:
C07C59/70
- cooperative:
C07C59/68; C07C59/70; C07D207/337; C07D209/42; C07D235/28; C07D239/22; C07D307/68; C07D317/60; C07D471/04; C07D493/04; G01N27/447; G01N33/5011; G01N2333/47

其他

Patent application

ID号码

3409

国家/地区

德国

欲了解更多信息，请点击这里